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Abstract: The significance of plasma levels of total cholesterol (TC), triglycerides (TG) and each lipoprotein class 
namely chylomicrons, low density lipoproteins (LDL), very low density lipoproteins (VLDL), and high density lipoproteins 
(HDL) has been tested time and again for their reliability as diagnostic markers of dyslipidemia. The prevalence of 
dyslipidemia-related metabolic syndrome is associated with the risk of cardiovascular disease (CVD) and diabetes. This 
review will focus on the characteristics of major classes of lipoproteins (LPs) and their coexistence with TG and 
apolipoprotein as estimates of the intensity of metabolic syndrome. It will deal with the suitability of animal models for 
dyslipidemic studies that match with clinical conditions of diabetes, atherosclerosis and obesity. It also sums up 
published research and clinical case studies in support of the conceptual paradigm shift from the use of simple lipids to 
oxidized LDL (OxLDL) and apolipoproteins as diagnostic markers of dyslipidemia. Further, it briefly discusses the use of 
non-pharmacological approach such as exercise and diet as an effective means of management of dyslipidemia in 
human as well as subhuman species. Finally, it presents evidence for treatment of dyslipidemia with specific targets, LP 
and TG as the appropriate therapy only when non-pharamacological means fail to accomplish the standard lipid profile. 
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INTRODUCTION  
It is known that dyslipidemia involving abnormal 
blood lipid levels is an endocrine and metabolic 
disorder largely of lipoprotein overproduction or 
deficiency. The condition is associated with a target 
population world-wide that is at an increased risk of 
developing cardiovascular diseases (CVDs) and 
diabetes. Although dyslipidemia is related to genetic 
predisposition, a high percentage of the population 
acquires it from multifactorial causes such as obesity, 
diet and lifestyle habits. The rapid rise in metabolic 
syndrome (MS) resulting from dyslipidemia leading to 
major diseases, diabetes type–II (DM2) and coronary 
artery diseases (CAD) is positively correlated to 
sedentary lifestyle and obesity. In fact, the cluster of 
conditions- obesity, dyslipidemia, diabetes and 
hypertension together is termed “metabolic syndrome”. 
MS is a combination of lifestyle and environmental 
factors and notably, some populations exhibit greater 
risk factors for the development of MS. Here we review 
the role of major players namely lipids in the 
development of dyslipidemia because of their critical 
role in development of atherogenic dyslipidemia 
comprising of hypertriglyceridemia, low levels of high-
density lipoprotein (HDL) and predominate levels of 
low-density lipoprotein (LDL). 
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Lipids are a diverse group of compounds that are 
weakly soluble in the aqueous media of the cell. The 
important lipids are cholesterol, triglyceride and 
phospholipid. Cholesterol is a precursor of the steroid 
hormones and of the bile acids necessary for digestion. 
The liver produces approximately 70% of the 
cholesterol used by the body, and the other 30% 
comes from the diet. Cholesterol is synthesized 
endogenously in the liver through the microsomal 
enzyme, 3-hydroxy-2-methylglutaryl-COA reductase 
(this is the rate-limiting enzyme). Although cholesterol 
and triglycerides have important functions in the body, 
due to their insolubility they are packed into lipoproteins 
in order to allow for their transport. The center of a 
lipoprotein molecule is composed of cholesteryl esters 
(CE, a compound of cholesterol and a fatty acid), 
triglycerides (TG, a compound of glycerol and three 
fatty acids), fatty acids and fat-soluble vitamins like 
vitamin E. The terms "good" and "bad" cholesterol refer 
to high density lipoproteins (HDL) and low density 
lipoproteins (LDL) respectively. The latter is more 
susceptible to oxidative modification that is referred as 
oxidized low-density lipoprotein (ox-LDL) and therefore 
toxic to vascular endothelium.  
Fatty acids are usually ingested as triglycerides and 
the digestion products are absorbed primarily as free 
fatty acids (FFA) and 2-monoglycerides. However, a 
small fraction is absorbed as free glycerol and 
diglycerides. Once these substances cross the 
intestinal barrier, they are resynthesized into TG and 
packaged in to chylomicron (CM) or lipoproteins and 
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transported through the capillaries of the lymph system, 
the lacteals and into the blood. The CM binds to the 
membranes of adipocytes, hepatocytes and skeletal 
muscle where they are stored and sometimes oxidized 
for production of energy. In fact, the liver is a major 
organ for processing CM and liposomes into the 
various types of lipoproteins that are spherical complex 
particles made up of hundreds of protein and lipid 
molecules and vary in size from 10 to 1000 
nanometers. In general, as the density of lipoproteins 
increases, the size of the particles decreases.  
The outer layer of a lipoprotein is polarized and 
assists in transporting lipids in the blood. It consists of 
a hydrophilic layer of apolipoproteins, phospholipids 
and cholesterol. Apolipoproteins (apo)- apoB, apoC 
and apoE coat the lipoprotein particles. The apos are 
recognized by enzymes that can either process or 
remove lipids from the lipoproteins. For instance, apoC-
II activates lipoprotein lipase (LPL) which is efficient in 
removing TG from CM and very low density lipoprotein 
(VLDL). The formation of VLDL in the liver is a step-
wise lipidation by the apo B. To start the lipidation, the 
microsomal triglyceride transfer protein (MTTP) in the 
rough endoplasmic reticulum [1] forms the pri-mordial 
VLDL [2] and in turn gets converted to triglyceride-poor 
VLDL by further lipidation [3]. The triglyceride-poor 
VLDL is secreted from the hepatocytes as VLDL2 or 
lipidated to form triglyceride-rich VLDL1 [4], a process 
dependent on GTP-binding protein ADP-ribosylation 
factor 1(ARF-I) [5]. The final stages of VLDL formation 
takes place in the golgi complex [6,7] although some 
data also suggest that the endoplasmic reticulum (ER) 
is the site of final maturation of VLDL [8].  
High density lipoprotein (HDL) is another type of 
lipoprotein that collects cholesterol, glycerol and FAs 
from the blood or from the cells if cholesterol is 
abundant and transports them to the liver unlike VLDL. 
HDL is a lipoprotein involved in reverse cholesterol 
transport and the transfer of cholesteryl esters from 
atherogenic lipoproteins and peripheral tissues to the 
liver. This ‘reverse transport’ mechanism, however, 
depends on the interactions between HDL, apos and 
enzyme activity. HDL particles are synthesized and 
catabolized in the liver as well as the intestine. A 
circulating enzyme, lecithin-cholesterol acyltransferase 
facilitates the uptake of free cholesterol from HDL by 
esterification. The reaction produces a more 
hydrophobic core and hence increases the density of 
HDL particle. Another enzyme, cholesteryl ester 
transfer protein (CETP), mediates the transfer of CE 
from the HDL core and the circulating lipoproteins such 
as LDL. Lipoproteins are classified on the basis of their 
densities as shown in Table 1 
Adapted from Skipski [9]. TG, triglycerides; Chol, 
cholesterol; CE, cholesterol esters; PL, phospholipids; 
VLDL, very low density lipoproteins; IDL, intermediate 
low density lipoproteins; LDL, low density lipoproteins; 
HDL, High density lipoproteins 
Dyslipidemia is Classified into: 
1) Primary dyslipidemia: Condition is caused by 
mutations in a single gene (monogenic) or 
caused by multiple mutations (polygenic), which 
may have less effect when present alone. These 
disorders are characterized by overproduction of 
lipoproteins and/or reduced clearance from 
circulation. 
2) Secondary dyslipidemia: Clinical conditions 
associated with dyslipidemia with different 
grades of severity in absence of genetic 
disorder. These disorders are sub classified into:  
a) Hypercholesterolemia: Hyperthyroidism, 
obstructive liver disease, drugs, nephrotic 
syndrome, use of cyclosporine and thiazides. 
Table 1: Classification of Lipoproteins 
Lipid (%) 
Lipoprotein Density (g/dL)  
Diameter 
(nm) 
PL Chol CE TG 
Protein 
(%) 
Chylomicrons < 0.95 1000 ~8 ~1 ~3 85-88 1-2 
VLDL ~ 0.98 25-90 18-20 8-10  12-15 50-55 5-12 
IDL ~ 1.0 40 25-27 8-10 32-35 24-30 10-12 
LDL ~ 1.04 26 20-28 8-10 37-48 10-15 20-22 
HDL ~ 1.12 6-12.5 26-46 2-10 15-30 3-15 55 
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b) Hypertriglyceridemia: Obesity, diabetes 
mellitus, pregnancy, gastric bypass surgery; 
stress, sepsis, alcohol, glucocorticoids, use of 
beta blockers, glycogen storage disease and 
chronic renal failure 
c) Low HDL: Type-2 diabetes mellitus, 
rheumatoid arthritis, obesity, cigarette 
smoking anabolic steroids and use of beta 
blockers. 
The lipid content and composition of various 
lipoproteins are represented in Table 2 
Table 2: Composition of Phospholipids of Lipoprotein 
Classes 
Phospholipids 
% PL  
CM VLDL LDL HDL 
PC 57-80 60-74 64-69 70-81 
SM 12-26 15-23 25-36 12-14 
Lyso PC 4-10 ~5 3-4 ~3 
Other 6-7 6-10 7-10 5-10 
 
Adapted from Skipski [9]. PC, phosphatidyl choline; 
SM, sphingomyelin; LysoPC, lyso phosphatidyl choline; 
others, phosphatidyl ethanol amine, phosphatidyl 
leucine and phosphatidyl inositol  
CARDIOVASCULAR DISEASES AND DYSLIPIDE- 
MIA 
Cardiovascular disease (CVD) is the most common 
cause of death world-wide and hence an understanding 
of dyslipidemia as a potential risk factor in clinical 
settings is of utmost importance. One of the major 
predisposing factors for atherosclerosis is altered lipid 
profile that is reported in 70% of patients with 
premature coronary artery disease (CAD). Increased 
concentration of LDL or decreased levels of HDL are 
major risk factors of coronary atherosclerosis although 
TG is independently associated with the disease. Total 
cholesterol does not accurately predict the risk of CAD, 
since it represents the sum of all cholesterol carried not 
only by atherogenic lipopropteins (VLDL, IDL, and LDL) 
but also antiatherogenic lipoproteins (HDL). Hence, 
most often treatment depends on LDL cholesterol 
values which in turn take into consideration LDL 
heterogeneity. As a matter of fact, small, dense LDL 
(sdLDL) particles are known to be more atherogenic 
than large, buoyant LDL particles, and the extent of 
oxidation of LDL (OxLDL) determines its atherogen- 
ecity [10, 11]. It is known that plasma OxLDL is a better 
predictor of coronary heart disease (CHD) and acute 
coronary syndrome (ACS) based on studies in 115 
subjects who had undergone coronary angiography 
[12]. Further, it is known that apo B may be an even 
better predictor of CAD compared to just LDL [13]. 
Besides, LDL contains apolipoproteins (apo B-100) and 
some other lipoprotein alleles such as apo C-II, apo-C-
III, and apo E. Few particles are rich in triglycerides i.e., 
large VLDL, while others are smaller and contain 
cholesteryl esters i.e. small VLDL and IDL. It is well 
known that the remnant lipoproteins that contain apo C-
III are potentially atherogenic. Clinical studies have 
shown the differences in LDL particles by size, density, 
and composition between healthy subjects and CHD 
patients. One of the best known examples is the 
Quebec study, wherein male subjects who had an LDL 
size < 25.6 nm exhibited 2.2-fold increase in the 
ischaemic heart disease (IHD) when compared to 
those men whose particle size was >25.6 nm [14]. A 
study involving multivariate analyses has shown sdLDL 
particles as predictors of incidence of IHD independent 
of many other parameters, LDL cholesterol, TG, HDL 
cholesterol, apo B, and the total cholesterol-HDL ratio. 
In contrast, records from the Physicians’ Health study 
[15] suggest that sdLDL is not a strong risk factor after 
comparing the risk factors, small and dense LDL and 
TG for myocardial infarction (MI). The cases had 
sdLDL diameter, 25.6±0.9 nm (mean ± SD) compared 
to 25.9±8 nm in the controls. There were cases with 
higher TG levels, 168 versus 132 mg/dL. Therefore it 
has been suggested that the LDL diameter has an 
inverse correlation with TG and a high direct correlation 
with HDL-cholesterol. The study also concluded that 
non-fasting TG levels are strong independent 
predictors of risk of MI, especially with elevated 
cholesterol levels. There are a few studies that have 
held that sdLDL particles are related to their 
atherogenic properties [16,17]. However, sdLDL 
particles containing more of CE (phenotype B) are 
considered to be more atherogenic than buoyant LDL 
particles (phenotype A). 
In the past two decades it has been established that 
oxidative stress-dependent oxidation of LDL particles 
leads to atherosclerosis and that OxLDL serves as an 
additive to the global score of atherosclerosis based on 
age, gender, HDL-cholesterol, total cholesterol, and 
other conditions such as diabetes mellitus, smoking 
and hypertension [18-20]. For example, sdLDL and 
oxidative stress have been reported as cooperative 
factors in atherogenesis leading to CVD in dyslipidemic 
Japanese male and female patients aged above 60 
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years [21]. There are also reasons to believe that 
sdLDL is a strong risk factor for CAD since sdLDL 
particles can enter the arterial wall more easily and 
bind to arterial proteoglycans [22] and are subjected to 
oxidative modifications leading to macrophage uptake 
[23]. 
Studies on TG-rich lipoproteins have discovered 
that hypertriglyceridemia is an independent risk factor 
for the development of CVD [24]. The size of 
lipoproteins actually determines their ability to enter the 
arterial intima through the endothelial barrier. For 
instance, sdLDLs of 20 to 60 Svedberg flotation units, 
Sf and IDLs of Sf 12 to 20 enter the intima unlike the 
chylomicrons and large VLDLs which are about 60 to 
400 Sf. Results from the Monitored Atherosclerosis 
Regression Study (MARS) have provided evidence for 
a positive correlation between the progression of CADs 
and TG-rich lipoprotein remnants [25]. A substudy of 
the Cholesterol and Recurrent Events (CARE) in 
patients with MI and on provastin, showed average 
LDL concentrations at 115 to 174 mg/dL and baseline 
concentrations of VLDL lipids, and apo E in VLDL+LDL 
and in HDL. These patients when compared to those 
who had earlier MI and patients who did not have any 
cardiovascular event during the 5 years of follow-up 
has shown that plasma VLDL and apo C-III in VLDL 
and LDL, are more reliable and specific markers of 
CHD risk than plasma TG [26].  
DYSLIPIDEMIA AND ADIPOSITY 
Fat distribution in the body has an important role on 
metabolic and cardiovascular risk factors. It is known 
that increased abdominal fat is a potent risk factor for 
CAD, diabetes type II (DM2), hypertension and stroke. 
The National Cholesterol and Education Program 
(NCEP) has included obesity, waist circumference, 
>102 cm in men and > 88 cm in women, as a 
component of common cluster that contributes to MS. 
The abdominal fat referred as visceral fat is related to 
hyperinsulinism, insulin resistance, raised plasma 
FFAs, hypertension, thrombosis, hypertriglyceridemia, 
sdLDL particles, and concomitant reduction in HDL. 
However, elevated LDL cholesterol is not considered 
as a marker of dyslipidemia. Elevated apo B indicative 
of increased number of sdLDL (VLDL and LDL) is 
recognized as a more reliable indicator of dyslipidemia. 
Obesity leads to over secretion of TG-rich VLDL 
particles and an increased FFA uptake in the liver 
which stimulates the secretion of apo-B-containing 
particles and hence hypertriglyceridemia [27]. In the 
presence of elevated TGs, LDL particles become 
enriched in TGs at the expense of core cholesteryl 
esters. The hepatic lipases act to hydrolyze these TG-
rich LDL leading to sdLDL particles, a well established 
risk factor for MI.  
FAMILIAL COMBINED HYPERLIPIDEMIA (FCHL) 
This type of hyperlipidemia is a genetic disorder and 
is associated with 1.7 to 10-fold elevated risk of CAD 
[28]. Studies on patients with MI have shown 11% 
prevalence of FCHL without premature CAD and 10-
14% prevalence of FCHL in patients with premature 
CAD [29]. In FCHL patients, there is excess generation 
of apo B in lipoproteins, VLDL, IDL and LDL with 
reduction of HDL production. This disorder is 
expressed after the third decade and is usually thought 
of in terms of central adiposity. It is also associated 
with increased insulin resistance, abdominal obesity 
and hypertension, all of which are characteristic of 
metabolic syndrome [30-32].  
DYSLIPIDEMIA AND DIABETES  
It is known that the incidence of several types of 
CVDs happen in patients with either type 1 (DM 1) or 
type 2 (DM 2). Development of dyslipidemia is known 
to signal the onset of diabetes which is essentially the 
occurrence of high TGs and LDL levels with low levels 
of HDL. In DM2, LDL is converted to smaller, more 
atherogenic sdLDL which in contrast to DM1, is not 
rectified with glycemic regulation [33]. It is now 
established with certainty that the onset of diabetic 
dyslipidemia is related to insulin effects on hepatic 
apoprotein synthesis, regulation of LpL, CETP action, 
and insulin influence on muscle and adipose tissue. 
DM2 patients are known to be at high risk of CAD and 
hence treated aggressively for lipid lowering therapies 
[34, 35]. 
ANIMAL MODELS OF DYSLIPIDEMIA 
Animal models have been utilized to understand 
dyslipidemia in humans especially for antiatherogenic 
drug target delivery and as validation model for 
dyslipidemia. Among the models of dyslipidemia 
abnormal lipid profiles and atherosclerosis have been 
studied extensively and a number of wild-type, naturally 
defective, and genetically modified animal species such 
as rabbits, mice, pigeons, dogs, pigs and monkeys 
have been characterized [36,37]. In humans, the 
fractional esterification rate in apolipoprotein B-
depleted plasma FER(HDL) has been demonstrated to 
correlate with the quality of LDL particles. Plasma lipid 
10    International Journal of Cardiology and Lipidology Research, 2017, Vol. 4, No. 1 Devi and Jyothi 
profiles and FER(HDL) values have been characterized 
in some species namely, cat, pigs, rabbits and guinea 
pigs and wide variations with a positive correlation are 
seen with FER(HDL) and TG, but not with HDL [38].  
Genetic hyperlipidemic disorders in Watanabe 
rabbits and in transgenic mice and in primate, Macaca 
nigra are useful models for studying interactions 
between diabetes and AS (atherosclerosis) [39]. 
Plasma lipoproteins and FA compositions have been 
studied and reported for five mouse strains, six other 
non-primate species, and four non-human primate 
(NHP) species [40]. Such studies on animal models of 
dyslipidemia are of prime importance since the success 
rate of drug development has not gone beyond statins 
and the major cause for this has been the limitations of 
the efficacy of treatments in the clinics [41]. 
Recognizing the importance of statins in alleviating 
plasma LDL for treatment of dyslipidemia in humans, 
studies by Yin et al [40] on simvastatin treatment in 
several species of animals have demonstrated that 
non-human primates (NHPs), followed by dogs are the 
animal models that are the closest match to human 
dyslipidemia. For practical and routine purposes, data 
obtained by Strack et al. [42] have shown hamster and 
dog as useful models for target validation in 
dyslipidemia. For the subset of dyslipidemic population 
with high TG levels, the closest matches are hamster 
and db/db mouse for use in drug validation. Animal [43] 
and tissue culture [44] studies too have suggested that 
fatty acids modulate apoB secretion in the liver.  
It is possible to study dyslipidemia in animals by 
streptozotocin or alloxan treatment [45, 46], or by 
maintaining the animals on a high fat diet [47] or by 
intralipid administration [48]. Animal models of disease 
therefore permit us to study the initiation and 
progression of pre-clinical stages of dyslipidemia and 
relevant information can be obtained for treatment and 
prevention since these models mimic human disease 
closely.  
The use of animal models in lipid metabolomics has 
been summarized in Table 3 
THERAPEUTIC INTERVENTIONS FOR TREATMENT 
OF DYSLIPIDEMIA 
Although at present drug treatment has been an 
effective therapy for overcoming dyslipidemia, concern 
for safety has driven many clinicians and researchers 
to prefer non-pharmacological therapies [49-52]. This 
part of the chapter briefly examines the cholesterol 
lowering efficacy of the NCEP and the 
recommendations of the Adult Treatment Panel III 
(ATP-III) about certain therapies in place of drug 
therapy. Another approach relates to the modification in 
Table 3: Animal Models of Dyslipidemia 
S. No Animal Models Studies References 
1 Rats and mice Metabolic syndrome, dyslipidemia and atherosclerosis [70] 
2 Mice, rat, hamster, rabbit dog and monkey Relationship between plasma HDL level and CETP activity  [71]  
3 Rabbits CETP inhibition and reduction of atherosclerosis [72]  
4 Rabbits Pharmacological modification of CETP in atherogenic dyslipidemia [73]  
5 CF rats Hyperlipidemic model in small animals through high fat diet obesity, hyperlipidemia, dyslipidemia and insulin intolerance [74]  
6 Hamster, rat, db/db mouse, dogs, rabbit, ZDF rat, humans Plasma lipoproteins, lipid fractions and fatty acid composition [75]  
7 Humans, rats, swine, rabbits monkeys, swine, dogs, hamsters dogs, hamsters 
Effect of n-3 fatty acids on triglyceride levels is seen in rats and swine 
but rarely seen in mice, rabbits, monkeys, dogs, and hamsters [40] 
8 Psammomys (rodent model of obesity) type 2 diabetes Lipid component and other characteristics of metabolic syndrome [76]  
9 WHHL rabbits Use of transgenic rabbits to study human atherosclerosis [77]  
10 WHHL rabbits Endothelial lipase and HDL metabolism [78] 
11 Obese SHR rats Metabolic syndrome, non-insulin dependent [79] 
12 Yucatan swine Diabetic dyslipidemia and LDL [80] 
CF, Carworth Farms; CETP, Cholesteryl ester transfer protein; db/db mouse, diabetic dyslipidemia; HDL, high density lipoprotein;  
LDL, low density lipoprotein; WHHL, Watanabe Heritable Hyperlipidemic rabbits; SHR, spontaneously hypertensive rats; ZDF, Zucker diabetic fatty rats. 
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lifestyle which is termed Therapeutic Lifestyle Changes 
(TLC). This involves one or more of the following: 
a) Reducing total fat intake to 25-35% daily energy 
low saturated fat diet combined with exercise  
b) Lowering saturated fat intake to 7% daily energy 
c) Reducing cholesterol intake to 200 mg/day  
d) Using nutritional supplementation such as fish oil, 
bran, and oats combined with exercise 
The combination therapies are most effective since 
exercise and diet can elicit complementary effects on 
the lipid profile. Diet therapies, with some exceptions, 
are effective in lowering total TC and LDL 
concentrations, while exercise interventions increase 
HDL and decrease TG levels. The synergistic effects of 
exercise and supplements in lowering LDL, TG and 
improving HDL have been well demonstrated as a 
function of age in laboratory rats [53, 54]. Specific 
interventions, which comprise low saturated fat diets 
combined with exercise lower TC, LDL-C, and TG 
concentrations by 7–18, 7–15, and 4 –18 %, 
respectively, while increasing HDL-C levels by 5–14 %. 
However, when nutritional supplements are combined 
with exercise, TC, LDL-C, and TG concentrations 
decrease by 8–26, 8 –30, and 12–39%, respectively, 
while increasing HDL-C levels by 2–8% [55]. These 
findings suggest that combination lifestyle therapies are 
an efficacious, preliminary means of improving 
cholesterol levels in those diagnosed with dyslipidemia, 
and should be implemented in place of drug therapy. 
Several publications report on the efficiency of 
aerobic exercises to improve the lipid profile. The 
relationship between physical exercise and 
dyslipidemia control is yet to be clarified. A Meta 
analysis assessing around 51 studies have indicated 
no direct relationship between the intensity of exercise 
and improvement in the lipid profile, i.e., there is no 
dose response relationship [56]. Other studies have 
shown that the benefits of physical exercise are 
primarily on the control of body adiposity and 
subsequent obesity prevention, which would result in a 
better lipid profile [57, 58]. In addition, studies on the 
effects of the amount and intensity of exercise on 
lipoproteins have shown that the amount of exercise, 
and not the intensity, promotes beneficial effects on 
plasma levels of lipoproteins [59, 60]. Hence, the 
beneficial effect of exercise on a variety of lipid and 
lipoprotein variables is seen most clearly with the high 
amount of high-intensity exercise. These studies 
corroborate the findings which show that the 
maintenance of physical activity throughout life 
(childhood, adolescence and adulthood) promotes the 
prevention of dyslipidemia and associated diseases. 
DISCUSSION 
The progressive escalation of metabolic syndrome 
has created many health concerns. Lowering LDL 
cholesterol has been an essential priority in the 
management of dyslipidemia in patients with type 2 
diabetes, more so, in those with or without at risk for 
CVD. The occurrence of metabolic syndrome is related 
with an increased incidence of coronary heart disease 
(CHD) and myocardial infarction in males and females 
as well. Dyslipidemia is a part of metabolic syndrome 
since both these terms encompass hypertrigly- 
ceridemia (serum triglycerides ≥ 150 mg/dl) and a low 
HDL cholesterol (<40 mg/dl for men and <50 mg/dl for 
women or HDL-C<35 mg/dl for men and <40 mg/dl for 
women by WHO). It is now recognized that the 
abnormalities of lipoprotein metabolism, namely, 
elevated TG, VLDL and ILDL levels, occur together 
than individually. Clinical studies report that many 
patients with CVDs are not properly treated for their 
dyslipidemia disorder, ‘Atherogenic Lipid Triad’ that is 
characterized by high serum TG level, low serum HDL 
level, and high LDL level. All of these can exacerbate 
increased incidence of diabetes [61]. More importantly, 
increased insulin resistance results in deficiency of 
lipoprotein lipase, an enzyme responsible for low 
clearance of fasting and postprandial triglyceride-rich 
lipoproteins (TRLs), and decreased production of HDL. 
All these are major contributors to the CVDs in subjects 
with type 2 diabetes [62]. If the LDL/HDL ratio is >5, 
then increased TG levels is known to confer an 
additional risk of CHD as analyzed from studies of the 
Helsinki Heart Study [63]. It is now certain that the base 
risk prediction of CADs and treatment approaches must 
be on a complete lipid profile and not by cholesterol or 
LDL determination. In order to explain the involvement 
of LDL cholesterol in CHDs, it is pertinent to 
understand the endothelial events. LDL entry through 
the endothelium modifies it by stimulating 
macrophages chemoattractant protein-1 (MCP-1) in 
order to recruit monocytes and scavenge receptors that 
take up to form foam cells. The foam cells synthesize 
growth factors and adherence proteins. HDL is also 
known to inhibit ox-LDL synthesis, the cytokine-induced 
expression of adhesion proteins and MCP-1. HDL is 
also anti-thrombotic and anti-apoptotic. Interestingly, it 
has been noted and well accepted that a 1% increase 
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in HDL-cholesterol will result in 1% alleviation in 
coronary disease events, and even more interesting is 
the fact that it is irrespective of the LDL-cholesterol 
level [64].  
Considering, the pharmacotherapeutic aspects, 
using statin monotherapy has proved to be 
unsuccessful towards achieving the required lipid levels 
as reported by the ACCORD (The Action to Control 
Cardiovascular Risk in Diabetes) study. A concomitant 
outcome of this study on atherogenic dyslipidemia is 
that fibrates in combination with statins are efficient risk 
reducers of cardiovascular events [65]. Currently, 
dyslipidaemia has a high worldwide prevalence, and 
many patients are turning to alternatives to 
pharmacotherapy to manage their lipid levels. 
However, lifestyle modification is considered of utmost 
priority in all patients to reduce cardiovascular risk and 
can be initiated before pharmacotherapy in primary 
prevention of CVD.  
One other approach for lowering LDL is through 
many functional foods and natural health products such 
as soy protein, green tea, plant sterols, probiotic 
yogurt, marine-derived omega-3 fatty acids and red 
yeast for potential lipid-lowering properties [66] 
although not to the same extent as statins. We shall 
discuss one such functional food i.e. probiotics. 
Probiotics are “Live microorganisms which when 
administered in adequate amounts confer a health 
benefit on the host” as defined by the Expert Panel 
commissioned in 2001 by the Food and Agriculture 
Organization of the United Nations, and supported by 
the World Health Organization [67]. Importantly, 
probiotics have also been studied for their cholesterol-
lowering effects in animal and human studies. A study 
by Xiao et al. [68] has shown that Bifidobacterium 
longum BL1 decreases serum TC, LDL-cholesterol, 
and TG, and increases HDL-cholesterol in humans. A 
recent study by Kim et al. [69] on experimentally-
induced hypercholesterolemia in rats with a combined 
treatment with probiotic mixtures (PM), two strains 
belonging to the species Lactobacillus (L. reuteri and L. 
plantarum) and Bifidobacterium (B. longum, B. lactis, 
and B. breve) for eight weeks signifies lowering of TC, 
LDL and TG but with increases in HDL. PM reduced 
expressions of cholesterol synthesis-related proteins 
such as sterol regulatory element-binding protein 1 
(SREBP1), fatty acid synthase (FAS), and acetyl-CoA 
carboxylase (ACC) in the liver were the underlying 
mechanisms for these modifications.  
Additional research is, however, warranted in the 
use of functional foods, which should incorporate large, 
high-quality randomized controlled trials with long 
follow-up periods to investigate associations with 
cardiovascular end points inclusive of LDL cholesterol.  
CONCLUSION 
To sum up, dyslipidemia represents abnormal levels 
of lipids transported by lipoproteins in the blood. 
Hyperliproteinemia/hyperlipidemia refers to abnormal 
levels of total cholesterol, LDL-the bad-cholesterol, or 
triglycerides as well as too low HDL–the good 
cholesterol. This review has attempted to provide a 
comprehensive report on the importance of the lipid 
profile, the cause-effect relation between coronary 
artery diseases and diabetes, the synergistic effects of 
physical activity and dietary manipulations as non-
pharmacological means of regulating lipids. However, 
additional studies are indeed required to account for 
the increase in lipoproteins with normal aging, which 
increases the risk of the mentioned diseases. Overall, 
the world-wide prevalence of the dyslipidemia–related 
pathological conditions makes it essential that accurate 
lipid profiling is crucial in order to classify individuals 
who are at risk of dyslipidemia-related diseases.  
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